The possible deal is valued to be approximately $20 billion, representing one of the biggest healthcare acquisitions in recent history, according to the news report. Although neither company has disclosed details about the discussion, shares of Synthes surged 6.2 percent on Friday amid the speculation.
While Johnson & Johnson has been acquiring companies, such as neurovascular stent-maker Micrus Endovascular, to boost its struggling medical device business, Synthes has demonstrated strong financial performance. Last year, the device company reported sales of $3.69 billion, representing an 8.6 percent increase from the previous year, according to the news report.
Read the news report about Johnson & Johnson and Synthes.
Read other coverage about Synthes:
– Synthes Reports $975.8M in 4Q Global Revenues, 9.4% Increase
– Synthes Acquires U.S. Surgical Tools Manufacturer
– Appeals Court Awards Synthes $21M in Patent Dispute Against Medtronic
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.